AGC Biologics to supply plasmid DNA starting material for Pfizer-BioNTech COVID-19 vaccine for the Omicron variant; first batches of the new vaccine are expected to be ready by end of March 2022

Sample article from our Health Care Sector

February 8, 2022 (press release) –

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility.
 
According to a recent news release from Pfizer and BioNTech, the companies have started to develop an Omicron-based COVID-19 vaccine with first batches expected to be ready for delivery by end of March 2022.

“We are proud to continue to support BioNTech and supply them with pDNA materials for their vaccine production, as a part of the fight against new pandemic variants,” said AGC Biologics Chief Executive Officer, Patricio Massera. “Our pDNA services are a part of our growing global Cell and Gene Therapy offering that includes the development and manufacturing of cell therapies, viral vectors, and messenger RNA.”

“This type of work is what drives us every day,” says AGC Biologics General Manager, Heidelberg, Dieter Kramer. “We appreciate this opportunity to help make a difference in the lives of people around the world and produce life-saving treatments.”

The AGC Biologics Heidelberg facility has more than 20 years of experience delivering a wide range of programs for customers. The site is the company’s Center of Excellence for pDNA production, and a central part of the AGC Biologics global network of cell and gene therapy-focused facilities, with additional locations in Milan, Italy and Longmont, Colorado, USA.

For more information on AGC Biologics’ Plasmid DNA offering visit www.agcbio.com/plasmid-dna. To learn more about the company’s broader cell and gene therapy services visit www.agcbio.com/cell-therapy.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.